Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.
暂无分享,去创建一个
D. Niederwieser | M. Montemurro | C. Kessler | M. Kirsch | H. Al-Ali | H. Wolf | G. Dölken | G. Maschmeyer | W. Krüger | S. Vogelgesang | T. Kiefer | H. Schroeder | C. Hirt | C. Busemann | C. Späth | F. Schüler | R. Herbst | K. Helke | H. Schroeder | G. Dölken
[1] K. Hoang-Xuan,et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? , 2011, Journal of Neuro-Oncology.
[2] E. Thiel,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.
[3] F. Feuerhake,et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P. Wen,et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma , 2007, Journal of Neuro-Oncology.
[5] D. Niederwieser,et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] E. Wong. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide , 2005, Neurology.
[7] D. Finkelstein,et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Mason,et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. , 2004, European journal of cancer.
[9] M. van Glabbeke,et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Armitage,et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Deangelis,et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Dichgans,et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma , 2000, Neurology.
[13] J. Blay,et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Nelson,et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. , 1992, International journal of radiation oncology, biology, physics.